Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY
Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY
For marginal zone lymphoma (MZL) Rituximab in combination with conventional chemotherapy is
 widely used for those patients who fail local therapy or do not qualify for such. Depending
 on the MZL subtype Rituximab/chemotherapy is able to induce in part long remissions, but does
 not prevent relapse later on. In addition, chemotherapy associated toxicity is often
 problematic in MZL patients, who are mostly of advanced age. Thus, chemotherapy-free
 approaches are highly attractive for this patient group. Rituximab single agent is a widely
 used chemotherapy-free approach in MZL, but was significantly inferior compared to
 Rituximab/chlorambucil in a large randomized prospective clinical trial in treatment naïve
 MZL with a CR rate of 55.8% vs. 78.8%, respectively (P < 0.001). Thus, it is the major aim to
 develop chemotherapy-free approaches for MZL, which approach or surpass efficacy of
 rituximab/chemotherapy combinations, but avoid chemotherapy associated toxicities.

 Checkpoint inhibitors such as Pembrolizumab have revolutionized cancer treatment and have
 also shown first encouraging results in Non-Hodgkin lymphomas. Based on these observations it
 is the aim of this study to test the toxicity and efficacy of Pembrolizumab in combination
 with the anti-CD20 antibody Rituximab in patients with newly diagnosed or relapsed MZL in
 need of treatment, who are not eligible or failed local therapy, following the assumption
 that this novel chemotherapy-free combination is significantly more efficient than Rituximab
 single agent therapy and at least as efficient as rituximab/chemotherapy, but avoids
 chemotherapy-related toxicity.
For marginal zone lymphoma (MZL) Rituximab in combination with conventional chemotherapy is
 widely used for those patients who fail local therapy or do not qualify for such. Depending
 on the MZL subtype Rituximab/chemotherapy is able to induce in part long remissions, but does
 not prevent relapse later on. In addition, chemotherapy associated toxicity is often
 problematic in MZL patients, who are mostly of advanced age. Thus, chemotherapy-free
 approaches are highly attractive for this patient group. Rituximab single agent is a widely
 used chemotherapy-free approach in MZL, but was significantly inferior compared to
 Rituximab/chlorambucil in a large randomized prospective clinical trial in treatment naïve
 MZL with a CR rate of 55.8% vs. 78.8%, respectively (P < 0.001). Thus, it is the major aim to
 develop chemotherapy-free approaches for MZL, which approach or surpass efficacy of
 rituximab/chemotherapy combinations, but avoid chemotherapy associated toxicities.

 Checkpoint inhibitors such as Pembrolizumab have revolutionized cancer treatment and have
 also shown first encouraging results in Non-Hodgkin lymphomas. Based on these observations it
 is the aim of this study to test the toxicity and efficacy of Pembrolizumab in combination
 with the anti-CD20 antibody Rituximab in patients with newly diagnosed or relapsed MZL in
 need of treatment, who are not eligible or failed local therapy, following the assumption
 that this novel chemotherapy-free combination is significantly more efficient than Rituximab
 single agent therapy and at least as efficient as rituximab/chemotherapy, but avoids
 chemotherapy-related toxicity.

 The objective of the trial is to test the efficacy and toxicity of treatment with
 Pembrolizumab and Rituximab in patients with MZL in need of treatment, who have failed or are
 not eligible for local therapy or relapsed. For efficacy the rate of complete remissions
 (according to the GELA criteria for gastric MALT or to the Cheson 2007 criteria for nodal and
 splenic MZL) after end of treatment (18 cycles) will be primarily analyzed. For toxicity
 assessment treatment associated adverse events, quality of life and cumulative incidence of
 secondary malignancies will be documented.

 This study is a European multicenter, single-arm, open-label, phase II trial of 18 cycles of
 Pembrolizumab and Rituximab in patients aged ≥ 18 years with previously untreated or relapsed
 MZL in need of treatment.

 Primary endpoint is the complete response (CR rate (CRR) determined after end of treatment
 (18 cycles).

 The study flow will be as follows:

 -  Previously untreated or relapsed patients will be screened for eligibility for the
 trial. If the patient is eligible for the study, the patient will be registered before
 the first cycle of treatment.

 -  Patients who progress at any time point during treatment are considered as treatment
 failure. They will be followed up for overall survival until end of follow up period or
 death.

 -  Patients, who achieve at least a SD after treatment will be followed up for response
 until progression/relapse and for overall survival until death.

 It is expected that a total of 56 patients at approximately 15 investigator sites in Germany
 and 3 centers in Austria will be registered. Every patient will receive treatment over a time
 period of 18 cycles (each cycle lasts 3 weeks). Subsequently, patients will be monitored
 every 3 months for 2 additional years, subsequently every 6 months for three additional
 years. The follow-up phase will be shorter than 5 years if End of Study is reached before
 this time period.
Inclusion Criteria:

 Patients must have a proven pathological diagnosis of MZL, diagnosed by a reference
 pathology center.

 Patients must meet the following inclusion criteria to be eligible for participation in
 this study:

 -  Confirmed CD20 positive de novo or relapsed MALT Lymphoma in need of treatment
 following or being not eligible for local therapy (including surgery, radiotherapy and
 antibiotics e.g. for H. pylori-positive gastric lymphoma arisen at any extranodal
 site) OR

 -  Confirmed CD20 positive de novo or relapsed splenic MZL in need of treatment following
 or not being eligible for local therapy (including surgery and antiviral therapy for
 Hepatitis C Virus) OR

 -  Confirmed CD20 positive de novo or relapsed nodal MZL in need of treatment following
 or not being eligible for local therapy (radiotherapy). The need of treatment is
 applicable in the case of B symptoms, deterioration of peripheral blood counts due to
 lymphoma infiltration of the bone marrow, rapid enlargement of lymph nodes or
 compression of vital organs by bulky disease.

 For nodal MZL and extragastric MALT lymphoma:

 • At least one bi-dimensionally measurable lesion (>=1.5 cm in its largest dimension by
 CT/PET-CT scan or MRI)

 For splenic MZL (SMZL):

 In patients with splenic MZL, an enlarged spleen on CT scan and lymphoma cell infiltration
 has to be seen in bone marrow and/or peripheral blood.

 At least one of the following criteria must be fulfilled:

 -  Bulky progressive or painful splenomegaly

 -  one of the following symptomatic/progressive cytopenias: Hb < 10 g/dL, or Platelet
 count < 80.000 /µL, or neutropenia < 1000 /µL, whatever the reason (autoimmune or
 hypersplenism or bone marrow infiltration)

 -  splenectomised patients with rapidly raising lymphocyte counts, development of
 lymphadenopathy or involvement of extranodal sites if not being eligible for local
 therapy

 -  SMZL with concomitant hepatitis C infection which has not responded to or has relapsed
 after Interferon and/or Ribavirin and/or direct antiviral agents (patients positive
 for HCV antibody are eligible only if PCR is negative for HCV RNA)

 For gastric MALT Lymphoma:

 For gastric MALT lymphoma, the clinical evidence of the MZL as seen by gastroendoscopy is
 sufficient. There is no need to show a measurable lesion by CT scan or MRI.

 Inclusion is possible for patients with:

 -  H. pylori-negative cases following or being not eligible for local therapy (i.e.,
 surgery, radiotherapy or antibiotics) or after systemic therapy

 -  H. pylori-positive disease that has remained stable, progressed, or relapsed following
 antibiotic therapy

 Others:

 -  Age ≥ 18 years

 -  Life expectancy > 3 months

 -  Meet the following pretreatment laboratory criteria at the Screening visit conducted
 within 28 days of study enrollment (unless due to underlying lymphoma):

 -  Baseline platelet count ≥ 75 x 109/L (if not due to BM infiltration by the
 lymphoma), absolute neutrophil count ≥ 1.5 x 109/L.

 -  Hemoglobin ≥ 9.0 g/dL or ≥ 5.6 mmol/L (Criteria must be met without
 erythropoietin dependency and without packed red blood cell (pRBC) transfusion
 within last 2 weeks)

 -  International Normalized Ratio (INR) or Prothrombin Time (PT): ≤ 1.5 × ULN unless
 subject is receiving anticoagulant therapy as long as PT or PTT is within
 therapeutic range of intended use of anticoagulants

 -  Activated Partial Thromboplastin Time (aPTT): ≤ 1.5 × ULN unless subject is
 receiving anticoagulant therapy as long as PT or PTT is within therapeutic range
 of intended use of anticoagulants

 -  ASAT (SGOT): ≤ 2.5 times the upper limit of institutional laboratory normal value
 or ≤ 5 times the upper limit of institutional laboratory normal value in subjects
 with lymphoma in the liver.

 -  ALAT (SGPT): ≤ 2,5 times the upper limit of institutional laboratory normal value
 or ≤ 5 times the upper limit of institutional laboratory normal value in subjects
 with lymphoma in the liver

 -  Serum total bilirubin: ≤ 1.5 × ULN OR Direct bilirubin ≤ ULN for subjects with
 total bilirubin levels > 1.5 ULN (unless clearly related to the disease)

 -  Serum creatinine ≤ 1.5 × ULN OR ≥ 60 mL/min GFR or CrCl for subjects with
 creatinine levels > 1.5 × institutional ULN

 -  Negative HIV antibody

 -  Patients with occult or prior HBV infection (defined as negative HBsAg and
 positive total HBcAb) may be included if HBV DNA is undetectable, provided that
 they are willing to undergo monthly DNA testing. Patients who have protective
 titers of HBSAb after vaccination or prior but cured hepatitis B are eligible.

 -  Patients positive for HCV antibody are eligible only if PCR is negative for HCV
 RNA.

 -  For women of child-bearing potential only: Pregnancy β-HCG negative. Serum or
 urine β-HCG must be negative during screening and at study enrolment visit.

 -  Premenopausal fertile females must agree to use a highly effective method of birth
 control for the duration of the therapy up to 12 months after the last dose of
 Rituximab and through 4 months after the last dose of Pembrolizumab. A highly
 effective method of birth control is defined as those which results in a low failure
 rate (i.e. less than 1% per year) when used consistently and correctly such as
 combined (estrogen and progestogen containing) hormonal contraception associated with
 inhibition of ovulation (oral, intravaginal or transdermal), progestogen-only hormonal
 contraception associated with inhibition of ovulation (oral, injectable or
 implantable), intrauterine device (IUD), intrauterine hormone-releasing system (IUS),
 bilateral tubal occlusion, vasectomised partner or sexual abstinence. Contraception
 and pregnancy testing are required according the CTFG recommendations
 (http://www.hma.eu/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/CTFG/
 2014_09_HMA_CTFG_Contraception.pdf)

 -  Men must agree not to father a child for the duration of therapy and 6 months after
 and must agree to advice a female partner to use a highly effective method of birth
 control. According to CTFG recommendations, men must use condoms.

 -  Willingness and ability to comply with scheduled visits, drug administration plan,
 imaging studies, laboratory tests, other study procedures, and study restrictions

 -  Evidence of a personally signed informed consent indicating that the subject is aware
 of the neoplastic nature of the disease and has been informed of the procedures to be
 followed, the experimental nature of the therapy, alternatives, potential benefits,
 possible side effects, potential risks and discomforts, and other pertinent aspects of
 study participation

 Exclusion Criteria:

 The presence of any of the following will exclude a subject from enrolment:

 -  ECOG performance status ≥ 2

 -  History of a malignancy except for the following: adequately treated local basal cell
 or squamous cell carcinoma of the skin, cervical carcinoma in situ, superficial
 bladder cancer, asymptomatic prostate cancer without known metastatic disease and with
 no requirement for therapy or requiring only hormonal therapy and with normal prostate
 specific antigen for ≥ 1 year prior to study enrolment visit, other malignancy treated
 with a curative intent and currently in complete remission, for ≥ 3 years

 -  Central nervous system lymphoma, leptomeningeal lymphoma, or histologic evidence of
 transformation to a high-grade or diffuse large B-cell lymphoma

 -  Has had prior chemotherapy (systemic anti-cancer therapy), targeted small molecule
 therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not
 recovered (i.e., ≤ Grade 1 or baseline value) from AEs due to a previously
 administered agent

 -  Note: Subjects with ≤ Grade 2 neuropathy are an exception to this criterion and
 may qualify for the study

 -  Note: If a subject received major surgery, they must have recovered adequately
 from complications from the intervention prior to starting therapy

 -  Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of
 study enrolment visit

 -  Ongoing drug-induced liver injury, chronic active hepatitis B (HBV), alcoholic liver
 disease, non-alcoholic steatohepatitis, primary biliary cholangitis, extrahepatic
 obstruction caused by cholelithiasis, cirrhosis of the liver, or portal hypertension

 -  Treatment with any other investigational agent or participating in another clinical
 trial with an investigational product within 4 weeks prior to entering this study or
 within 5 x the half-life (t1/2) of the investigational product, whichever is longer

 -  Breastfeeding or Pregnancy

 -  Congestive heart failure > New York Heart Association (NYHA) class 2

 -  Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3
 months)

 -  Myocardial infarction less than 6 months before start of study medication

 -  Uncontrolled arterial hypertension despite optimal medical management

 -  Prior or ongoing clinically significant illness, medical condition, surgical history,
 physical finding, electrocardiogram (ECG) finding, or laboratory abnormality that, in
 the investigator's opinion, could adversely affect the safety of the subject or impair
 the assessment of study results

 -  Vaccination with a live vaccine within 30 days prior to start of therapy

 -  Arterial or venous thrombotic or embolic events such as cerebrovascular accident
 (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism
 within 3 months before the start of study medication

 -  Non-healing wound, ulcer, or bone fracture

 -  History or concurrent interstitial lung disease of any severity and/or severely
 impaired lung function (as judged by the investigator)

 -  Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with
 an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g.,
 CTLA-4, OX 40, CD137)

 -  Has received prior radiotherapy within 2 weeks of start of study treatment.
 Participants must have recovered from all radiation-related toxicities, not require
 corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted
 for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease

 -  Has known active CNS metastases and/or carcinomatous meningitis. Participants with
 previously treated brain metastases may participate provided they are radiologically
 stable, i.e. without evidence of progression for at least 4 weeks by repeat imaging
 (note that the repeat imaging should be performed during study screening), clinically
 stable and without requirement of steroid treatment for at least 14 days prior to
 first dose of study treatment

 -  Has a history of non-infectious pneumonitis that required steroids, or current
 pneumonitis

 -  History of anaphylaxis in association with previous administration of monoclonal
 antibodies or severe hypersensitivity (≥Grade 3) to the investigational medicinal
 products and/or any of its excipients

 -  Has active autoimmune disease that has required systemic treatment in the past 2 years
 (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive
 drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid
 replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a
 form of systemic treatment

 -  Has a known history of active TB (Bacillus Tuberculosis)

 -  Medical history of allogeneic stem cell transplant

 -  Ongoing alcohol or drug addiction or known psychiatric or substance abuse disorders
 that would interfere with cooperation with the requirements of the trial

 -  Diagnosis of Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)